Profile data is unavailable for this security.
About the company
Bloomage Biotechnology Corp Ltd is a China-based company primarily engaged in the research, development, production, and sales of hyaluronic acid and other bioactive products. The Company's products include raw materials, medical end products, functional skincare products, and functional foods. Raw materials include a series of bioactive products centered around hyaluronic acid, applied in pharmaceutical materials, personal care products, nutrition and health, and innovative business areas. Medical end products are divided into medical aesthetics and pharmaceutical categories, including ophthalmic viscoelastic agents, medical lubricants, soft tissue fillers, and medical skin protectants. Functional skincare products include single-use ampoules, various creams, lotions, masks, and hand masks. Functional foods include hyaluronic acid solutions and hyaluronic acid-based foods.
- Revenue in CNY (TTM)4.66bn
- Net income in CNY64.62m
- Incorporated2000
- Employees4.44k
- LocationBloomage Biotechnology Corp LtdNo.678 Tianchen StreetHigh-tech Development ZoneJI'NAN 250101ChinaCHN
- Phone+86 1 085670603
- Fax+86 1 065630000
- Websitehttps://www.bloomagebiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology Co Ltd | 1.18bn | 62.08m | 19.18bn | 1.15k | 304.44 | 7.84 | -- | 16.26 | 0.1489 | 0.1489 | 2.82 | 5.79 | 0.2305 | 1.61 | 3.38 | 1,025,174.00 | 0.5058 | 5.25 | 0.6383 | 6.47 | 51.53 | 56.22 | 2.19 | 17.55 | 0.9402 | 1.23 | 0.4935 | 21.32 | 8.74 | 20.58 | -6.57 | 11.23 | 23.50 | 3.20 |
| Joincare Pharmaceutical Group Ind. Co. | 15.20bn | 1.37bn | 20.87bn | 14.35k | 15.39 | 1.40 | -- | 1.37 | 0.7413 | 0.7413 | 8.24 | 8.13 | 0.4211 | 2.40 | 5.51 | 1,059,126.00 | 8.29 | 8.60 | 17.45 | 18.66 | 61.28 | 62.42 | 19.70 | 17.66 | 2.38 | -- | 0.1776 | 27.59 | -6.17 | 5.45 | -3.90 | 9.17 | 6.84 | 4.56 |
| Tasly Pharmaceutical Group Co Ltd | 8.35bn | 1.10bn | 21.92bn | 10.96k | 19.96 | 1.78 | -- | 2.63 | 0.7348 | 0.7348 | 5.59 | 8.24 | 0.525 | 1.83 | 7.50 | 761,658.60 | 6.44 | 5.86 | 7.91 | 7.26 | 65.70 | 58.62 | 12.26 | 10.61 | 3.12 | -- | 0.0642 | 56.80 | -2.03 | -14.86 | -10.78 | -0.9327 | -5.02 | 9.94 |
| Bloomage Biotechnology Corp Ltd | 4.66bn | 64.62m | 22.76bn | 4.44k | 338.86 | 3.20 | -- | 4.88 | 0.1394 | 0.1394 | 9.59 | 14.76 | 0.5431 | 1.12 | 8.61 | 1,048,475.00 | 0.719 | 8.43 | 0.827 | 9.97 | 70.71 | 75.45 | 1.32 | 12.34 | 1.42 | 40.02 | 0.0317 | 30.32 | -11.61 | 23.29 | -70.59 | -21.53 | 9.89 | -21.54 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.71bn | 468.07m | 23.52bn | 9.07k | 48.25 | 2.47 | -- | 2.70 | 0.3256 | 0.3256 | 6.00 | 6.35 | 0.4279 | 0.9611 | 3.17 | 960,689.80 | 2.18 | 5.67 | 3.15 | 7.93 | 59.76 | 60.79 | 5.10 | 11.66 | 0.7399 | 8.95 | 0.4519 | 31.74 | 14.91 | 12.12 | 34.74 | 14.46 | 18.47 | 6.58 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 742.28m | -133.34m | 24.99bn | 910.00 | -- | 21.75 | -- | 33.67 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 6.14bn | 1.65bn | 25.04bn | 5.03k | 15.11 | 1.81 | -- | 4.08 | 1.80 | 1.80 | 6.69 | 15.02 | 0.3543 | 2.99 | 3.59 | 1,222,407.00 | 9.53 | 15.19 | 11.67 | 19.57 | 75.44 | 81.73 | 26.91 | 26.02 | 5.18 | -- | 0.0437 | 46.90 | -16.96 | 2.93 | -10.32 | 9.30 | -20.43 | 11.19 |
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.14bn | 4.23k | 1,643.48 | 3.64 | -- | 4.95 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
Data as of Feb 13 2026. Currency figures normalised to Bloomage Biotechnology Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Sep 2025 | 6.96m | 1.45% |
| China Asset Management Co., Ltd.as of 30 Sep 2025 | 6.82m | 1.42% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Sep 2025 | 5.37m | 1.12% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.03m | 0.63% |
| China Merchants Fund Management Co., Ltd.as of 30 Sep 2025 | 2.50m | 0.52% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 1.88m | 0.39% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 1.61m | 0.34% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 1.22m | 0.25% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 1.21m | 0.25% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 1.21m | 0.25% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
